1H-Indole-3-carboxamide, N-ethyl- | 156741-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1H-Indole-3-carboxamide, N-ethyl-
• 英文别名: N-ethyl-1H-indole-3-carboxamide
• CAS: 156741-82-1
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD12193322
• 分子量: 188.23
• InChiKey: YJDFJNILGYBKIT-UHFFFAOYSA-N

物化性质

• 沸点：
  462.8±18.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  44.9
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• [EN] IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA<br/>[FR] MODULATEURS D'IMIDAZOPYRIDAZINE D'IL-12, IL-23 ET/OU IFN-ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018093968A1

  公开（公告）日：2018-05-24

  Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

  式(I)的化合物或其立体异构体或药用盐在调节IL-12、IL-23和/或IFNα方面具有用处，通过作用于Tyk-2引起信号传导抑制。
• IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA
  申请人：Bristol-Myers Squibb Company

  公开号：EP3541817B1

  公开（公告）日：2020-12-23
• TREATMENT AND PROPHYLAXIS
  申请人：Levesque Jean-Pierre

  公开号：US20110002881A1

  公开（公告）日：2011-01-06

  This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
• COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：US20160193294A1

  公开（公告）日：2016-07-07

  This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.
• NUCLEIC ACID-SCAFFOLDED SMALL MOLECULE LIBRARIES
  申请人：LEVY Matthew

  公开号：US20160266133A1

  公开（公告）日：2016-09-15

  Methods and compositions are provided for identifying novel ligands for a protein target.